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We analyzed data for 170 patients in South Korea who had 
laboratory-confirmed	 infection	 with	 Middle	 East	 respira-
tory syndrome coronavirus. A longer incubation period was 
associated	with	a	reduction	in	the	risk	for	death	(adjusted	
odds	 ratio/1-day	 increase	 in	 incubation	period	0.83,	95%	
credibility interval 0.68–1.03).
The incubation period of an infectious disease is the time from the moment of exposure to an infectious agent 
until signs and symptoms of the disease appear (1). This 
major biological parameter is part of the case definition 
and is used to determine duration of quarantine and inform 
policy decisions when mathematical modeling is used (2). 
Incubation periods vary from person to person, and their 
distribution tends to be right-skewed and unimodal (3). 
Variability in incubation periods for infection with Middle 
East respiratory syndrome coronavirus (MERS-CoV) has 
been described (4–8). Previous studies have not examined 
whether the length of the incubation period in a person has 
any correlation with subsequent clinical outcomes.
In 2015, South Korea had the largest outbreak of 
MERS-CoV infections outside the Arabian Peninsula (6). 
In a previous study, we reported that patients who died of 
severe acute respiratory syndrome (SARS) coronavirus 
infection had a shorter incubation period compared with 
infected patients who survived (9). The objective of this 
study was to examine the association between severity of 
MERS-CoV illness and length of incubation period.
The Study
We retrieved publicly available data from the Korea Center 
for Disease Control and Prevention, the Korean Ministry of 
Health and Welfare, the World Health Organization, and 
local news reports in South Korea to compile a list of all 
confirmed cases that had been reported by July 26, 2015 
(6). Exposure data were available for 109 (64%) of 170 pa-
tients. For most cases, information on exposure was record-
ed as intervals >2 days during which infection was believed 
to have occurred, rather than exact dates of presumed infec-
tion. For the subset of patients without available exposure 
data, we assumed that their incubation time was 0–21 days 
because 21 days was the longest incubation period report-
ed (9,10). Data for patients is provided in online Techni-
cal Appendix 1 (http://wwwnc.cdc.gov/EID/article/22/3/ 
15-1437-Techapp1.xlsx).
To estimate incubation period distribution, we fitted a 
gamma distribution that enabled interval censoring (6) by 
using Markov Chain Monte Carlo methods in a Bayesian 
framework (online Technical Appendix 2, http://wwwnc.
cdc.gov/EID/article/22/3/15-1437-Techapp2.pdf) (9). In 
this analysis and analyses described below, we specified flat 
priors for each parameter and drew 10,000 samples from 
the posterior distributions after a burn-in of 5,000 iterations.
To evaluate potential factors, such as age and sex, 
that could be associated with length of incubation period, 
we fitted a multiple linear regression model to the data 
with the log incubation period as response variable and 
age and sex as explanatory variables. To determine the 
association between incubation period and severity of 
disease, we first estimated the difference in mean incu-
bation period between patients who died and those who 
survived. However, this analysis could not account for 
potential confounders. Therefore, we specified a mul-
tivariable logistic regression model in which death was 
the binary response variable and predictors included age, 
sex, and the incubation time for each patient (9). We 
performed this analysis by using an exact likelihood ap-
proach and incubation times resampled from the 10,000 
posterior samples in each iteration (online Technical Ap-
pendix). All analyses were conducted by using R version 
3.0.2 (R Foundation for Statistical Computing, Vienna, 
Austria). Raw data and R syntax enabling reproduction 
of results are available from the Dryad Digital Repository 
(http://dx.doi.org/10.5061/dryad.v3456).
Of 170 patients in this study, 36 (21%) died. Mean pa-
tient age was 54.6 years, and 98 (58%) were male. Patients 
who died were significantly older than patients who sur-
vived (68.9 years vs. 50.8 years; p<0.001). No differences 
regarding age, sex, and case-fatality risk were observed 
between patients with or without recorded exposure data. 
We estimated a mean incubation period of MERS-CoV in 
all 170 patients of 6.9 days (95% credibility interval [CrI] 
6.3–7.5 days) by using a gamma distribution. Age and sex 
had no associations with incubation period.
The mean incubation period was 6.4 days (95% CrI 
5.2–7.9 days) for 36 patients who died compared with 7.1 
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days (95% CrI 6.3–7.8 days) for 134 patients who survived 
(Figure). The difference in means was 0.62 days (95% CrI 
-0.99 to 2.04 days). In the multivariable logistic regression 
model, we found that a longer incubation period was asso-
ciated with a marginally reduced risk for death (odds ratio 
0.83/1-day increase in incubation period, 95% CrI 0.68–
1.03/day) after adjustment for age and sex (online Techni-
cal Appendix 2 Table 2).
To examine sensitivity of our results, we also fitted 
the logistic regression models by using 3 categories for 
the incubation period. We observed similar results and a 
reduced risk for death associated with longer incubation 
periods (online Technical Appendix Table 2). Results were 
also consistent in the subset of 109 patients with recorded 
exposure intervals (online Technical Appendix Table 2).
Conclusions
We estimated the incubation period of MERS-CoV cases 
during the recent MERS outbreak in South Korea and 
found that patients who died had a shorter incubation pe-
riod than patients who survived. In a previous study, we 
found that the length of incubation period in patients in-
fected with SARS coronavirus was also correlated with se-
verity of the disease, with a shorter incubation period for 
patients who died (9). The pathogenesis of MERS-CoV and 
SARS coronavirus infection is similar (11), with a rapid 
progression to respiratory failure and intubation occurring 
≈1 week after onset of symptoms and up to 5 days earlier 
in MERS patients than in SARS patients (4,12). Moreover, 
high rates of hemoptysis were observed in patients infected 
with MERS-CoV, which suggests severe lung injury (4).
MERS-CoV also has higher replication rates and 
shows broader cell tropism in the lower human respiratory 
tract than severe acute respiratory syndrome coronavirus 
(13). These results suggest that a shorter incubation period 
could be related to a higher initial infective dose and conse-
quently to faster or greater pathogen replication. This find-
ing could lead to a more severe disease induced by more 
aggressive and damaging inflammatory responses (14). 
Closer monitoring of patients who have a shorter incuba-
tion period could be considered during such outbreaks.
Another potential explanation for our findings is that 
patients with longer incubation periods were identified 
and infection confirmed more quickly. This improvement 
in time to identification and admission to a hospital led to 
improved prognosis. Although longer incubation periods 
were correlated with shorter delays from onset to labora-
tory confirmation, we did not find evidence of a strong me-
diating effect of delay from onset to laboratory confirma-
tion on the risk for death. However, with the small sample 
size, there was limited statistical power to detect a small-
to-moderate effect.
Our study had some limitations. Our estimates of the 
incubation period were based on self-reported exposure 
data, which could be affected by recall bias. Moreover, 61 
patients (36%) included in our main analysis had missing 
exposure data, and inclusion in a Bayesian framework with 
a wide interval of 0–21 days was necessary. Both of these 
limitations could have reduced the statistical power of our 
study to identify an association. Finally, we did not have 
information on underlying medical conditions or the geo-
graphic location of cases, or the treatments that were given 
to cases, and these variables could have been associated 
with clinical outcomes.
In conclusion, we found an association between short-
er incubation periods among patients with MERS-CoV 
infection and a higher risk of death subsequently, similar 
to the association previously reported for severe acute re-
spiratory syndrome coronavirus (9). This association might 
occur because the duration of the incubation period is an 
early reflection of disease pathogenesis.
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Figure. Parametric estimates of incubation period distribution 
for	patients	who	died	of	infection	with	Middle	East	respiratory	
syndrome	coronavirus	(dashed	line)	and	patients	who	survived	
infection	(solid	line),	South	Korea,	2015.
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